Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1)

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Chung, Yuan Chiang ^a   Kuo, Jang Fang ^a   Wei, Wan Chen ^a,b   Chang, King Jen ^a   Chao, Wei Ting ^b   Tan, Ming ^c  

^a CHENG CHING GENERAL HOSPITAL   (Taiwan)

^b TUNGHAI UNIVERSITY   (Taiwan)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GREEN FLUORESCENT PROTEIN; PACLITAXEL; SMALL INTERFERING RNA; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; CAV1 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TRANSPORT; ENDOCYTOSIS; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE SECTION; TUMOR BIOPSY; VERY ELDERLY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DRUG EFFECTS; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAVEOLIN 1; CELL SURVIVAL; ENDOCYTOSIS; FEMALE; HUMANS; MAYTANSINE; MCF-7 CELLS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 84940486817     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133072     Document Type: Article

References (55)

1. Slamon DJ, Clark GM, Wong S.G., Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. Epub 1987/01/09. PMID: 3798106.
2. Slamon DJ, Godolphin W, Jones L.A., Holt JA, Wong SG, Keith DE, et al Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. Epub 1989/ 05/12. PMID: 2470152.
3. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2): 127-37. Epub 2001/03/17. doi:10.1038/35052073 PMID: 11252954.
4. Marty M, Cognetti F, Maraninchi D., Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23(19):4265-74. Epub 2005/05/25. doi:10.1200/jco.2005.04. 173 PMID: 15911866.
5. Chia S, Clemons M, Martin L.A., Rodgers A., Gelmon K, Pond GR, et al Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006; 24(18):2773-8. Epub 2006/05/10. doi:10.1200/jco.2005.03.8331 PMID: 16682726.
6. Robert N, Leyland-Jones B, Asmar L., Belt R, Ilegbodu D, Loesch D., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006; 24(18):2786-92. Epub 2006/06/ 20. doi:10.1200/jco.2005.04.1764 PMID: 16782917.
7. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007; 357(1):39-51. Epub 2007/07/06. doi:10.1056/NEJMra043186 PMID: 17611206.
8. Seidman A, Hudis C, Pierri M.K., Shak S., Paton V, Ashby M, et al Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20(5):1215-21. Epub 2002/03/01. PMID: 11870163.
9. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013; 5(1):13-21. Epub 2012/ 12/12. doi:10.4161/mabs.22854 PMID: 23221464; PubMed Central PMCID: PMC3564878.
10. Panowksi S, Bhakta S, Raab H., Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014; 6(1):34-45. Epub 2014/01/16. doi:10.4161/mabs.27022 PMID: 24423619; PubMed Central PMCID: PMC3929453.
11. Lewis Phillips G.D., Li G, Dugger D.L., Crocker LM, Parsons KL, Mai E, et al Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68(22): 9280-90. Epub 2008/11/18. doi:10.1158/0008-5472.can-08-1776 PMID: 19010901.
12. LoRusso PM, Weiss D, Guardino E., Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011; 17(20):6437-47. Epub 2011/10/18. doi:10.1158/1078-0432.ccr-11-0762 PMID: 22003071.
13. Verma S, Miles D, Gianni L., Krop IE, Welslau M, Baselga J, et al Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. Epub 2012/10/02. doi:10.1056/NEJMoa1209124 PMID: 23020162.
14. Hurvitz SA, Dirix L, Kocsis J., Bianchi GV, Lu J, Vinholes J, et al Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013; 31(9):1157-63. Epub 2013/02/06. doi:10.1200/jco.2012.44.9694 PMID: 23382472.
15. Krop IE, Kim SB, Gonzalez-Martin A, LoRusso P.M., Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(7):689-99. Epub 2014/ 05/06. doi:10.1016/s1470-2045(14)70178-0 PMID: 24793816.
16. Kovtun YV, Goldmacher VS Cell killing by antibody-drug conjugates. Cancer Lett. 2007; 255(2):232-40. Epub 2007/06/08. doi:10.1016/j. canlet.2007.04.010 PMID: 17553616.
17. Shaughnessy R, Retamal C, Oyanadel C., Norambuena A, Lopez A, Bravo-Zehnder M, et al. Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer. FEBS J. 2014; 281(9):2172-89. Epub 2014/03/07. doi:10.1111/febs. 12770 PMID: 24597955.
18. Parachoniak CA, Park M. Dynamics of receptor trafficking intumorigenicity. Trends Cell Biol. 2012; 22(5):231-40. Epub 2012/03/09. doi:10.1016/j.tcb.2012.02.002 PMID: 22397948.
19. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008; 8(11):835-50. Epub 2008/10/25. doi:10.1038/nrc2521 PMID: 18948996.
20. Khan EM, Heidinger JM, Levy M, Lisanti M.P., Ravid T., Goldkorn T. Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem. 2006; 281(20):14486-93. Epub 2006/01/13. doi:10.1074/jbc.M509332200 PMID: 16407214.
21. Wang Z. Mutual Regulation of Receptor-Mediated Cell Signalling and Endocytosis: EGF Receptor System as an Example 2012.
22. Shvets E, Ludwig A, Nichols BJ News from the caves: update on the structure and function of caveolae. CurrOpin Cell Biol. 2014; 29:99-106. Epub 2014/06/09. doi:10.1016/j.ceb.2014.04.011 PMID: 24908346.
23. Rothberg KG, Heuser JE, Donzell W.C., Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992; 68(4):673-82. PMID: 1739974.
24. Koleske AJ, Baltimore D, Lisanti MP Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA. 1995; 92(5):1381-5. Epub 1995/02/28. PMID: 7877987; PubMed Central PMCID: PMC42523.
25. Williams TM, Lisanti MP Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol. 2005; 288(3):C494-506. Epub 2005/02/05. doi:10.1152/ajpcell.00458.2004 PMID: 15692148.
26. Lee SW, Reimer CL, Oh P, Campbell D.B., Schnitzer JE. Tumor cell growth inhibition by caveolin reexpression in human breast cancer cells. Oncogene. 1998; 16(11):1391-7. Epub 1998/04/03. doi:10.1038/sj.onc.1201661 PMID: 9525738.
27. Fiucci G, Ravid D, Reich R., Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene. 2002; 21(15):2365-75. Epub 2002/ 04/12. doi:10.1038/sj.onc.1205300 PMID: 11948420.
28. Bouras T, Lisanti MP, Pestell RG Caveolin-1 in breast cancer. Cancer Biol Ther. 2004; 3(10):931-41. Epub 2004/11/13. PMID: 15539932.
29. Sloan EK, Stanley KL, Anderson RL Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004; 23(47):7893-7. Epub 2004/08/31. doi:10.1038/sj.onc.1208062 PMID: 15334058.
30. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, et al Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004; 15(12):5268-82. Epub 2004/09/24. doi:10.1091/mbc.E04-07-0591 PMID: 15385631; PubMed Central PMCID: PMC532009.
31. Sekhar SC, Kasai T, Satoh A., Shigehiro T, Mizutani A, Murakami H., et al. Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells. J Cancer. 2013; 4(5):391-401. Epub 2013/07/09. doi:10.7150/jca.6470 PMID: 23833684; PubMed Central PMCID: PMC3701809.
32. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014; 16(2):209. Epub 2014/06/03. doi:10.1186/bcr3621 PMID: 24887180; PubMed Central PMCID: PMC4058749.
33. Elzagheid A, Algars A, Bendardaf R., Lamlum H, Ristamaki R, Collan Y., et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol. 2006; 12(27):4304-9. Epub 2006/07/26. PMID: 16865770; PubMed Central PMCID: PMC4087739.
34. Chung YC, Wei WC, Huang S.H., Shih CM, Hsu CP, Chang KJ, et al Rab11 regulates E-cadherin expression and induces cell transformation in colorectal carcinoma. BMC Cancer. 2014; 14:587. Epub 2014/08/15. doi:10.1186/1471-2407-14-587 PMID: 25117932; PubMed Central PMCID: PMC4137074.
35. Park SS, Kim JE, Kim Y.A., Kim YC, Kim SW. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology. 2005; 47(6):625-30. Epub 2005/12/06. doi:10.1111/j.1365-2559.2005.02303.x PMID: 16324201.
36. Subik K, Lee JF, Baxter L, Strzepek T., Costello D, Crowley P, et al The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010; 4:35-41. PMID: 20697531; PubMed Central PMCID: PMCPMC2914277.
37. Barok M, Tanner M, Koninki K., Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011; 13(2):R46. Epub 2011/04/23. doi:10.1186/bcr2868 PMID: 21510863; PubMed Central PMCID: PMC3219209.
38. Pelkmans L, Burli T, Zerial M., Helenius A. Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell. 2004; 118(6):767-80. Epub 2004/09/ 17. doi:10.1016/j.cell.2004.09.003 PMID: 15369675.
39. Savage K, Lambros MB, Robertson D, Jones R.L., Jones C., Mackay A, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007; 13(1):90-101. Epub 2007/01/04. doi:10.1158/1078-0432.ccr-06-1371 PMID: 17200343.
40. Sloan EK, Ciocca DR, Pouliot N, Natoli A., Restall C, Henderson MA, et al Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 2009; 174(6):2035-43. Epub 2009/05/05. doi:10.2353/ajpath.2009.080924 PMID: 19411449; PubMed Central PMCID: PMC2684169.
41. Ma X, Liu L, Nie W., Li Y, Zhang B, Zhang J., et al. Prognostic role of caveolin in breast cancer: a metaanalysis. Breast. 2013; 22(4):462-9. Epub 2013/05/04. doi:10.1016/j.breast.2013.03.005 PMID: 23639584.
42. Mercier I, Lisanti MP Caveolin-1 and breast cancer: a new clinical perspective. Adv Exp Med Biol. 2012; 729:83-94. doi:10.1007/978-1-4614-1222-9 6 PMID: 22411315.
43. Chiu WT, Lee HT, Huang F.J., Aldape KD, Yao J, Steeg PS, et al Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res. 2011; 71(14):4932-43. doi:10.1158/0008-5472.CAN-10-4249 PMID: 21622714; PubMed Central PMCID: PMCPMC4170798.
44. Rao X, Evans J, Chae H., Pilrose J, Kim S, Yan P., et al. CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene. 2013; 32(38):4519-28. Epub 2012/11/07. doi:10.1038/onc.2012.474 PMID: 23128390; PubMed Central PMCID: PMC3787796.
45. Goetz JG, Lajoie P, Wiseman S.M., Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008; 27(4):715-35. Epub 2008/05/29. doi:10.1007/s10555-008-9160-9 PMID: 18506396.
46. Gornstein E, Schwarz TL The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology. 2014; 76 Pt A:175-83. doi:10.1016/j.neuropharm.2013.08.016 PMID: 23978385.
47. Jia-Jun T., Su-Mei L, Liang Y., Ju-Ke M, Ya-Kui M, Hai-Bo W, et al. Nimesulide inhibited the growth of hypopharyngeal carcinoma cells via suppressing Survivin expression. Head Neck Oncol. 2012; 4:7. doi:10.1186/1758-3284-4-7 PMID: 22453101; PubMed Central PMCID: PMCPMC3364892.
48. Rotin D, Margolis B, Mohammadi M., Daly RJ, Daum G, Li N, et al SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipaseC gamma. EMBOJ. 1992; 11(2):559-67. Epub 1992/02/01. PMID: 1537335; PubMed Central PMCID: PMC556487.
49. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003; 22(42):6570-8. Epub 2003/10/07. doi:10.1038/sj.onc.1206779 PMID: 14528282.
50. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001; 12 Suppl 1:S3-8. Epub 2001/08/28. PMID: 11521719.
51. Ben-Kasus T., Schechter B, Lavi S., Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA. 2009; 106(9):3294-9. Epub 2009/02/17. doi:10.1073/pnas.0812059106 PMID: 19218427; PubMed Central PMCID: PMC2651295.
52. Sorkin A, Goh LK Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2008; 314(17): 3093-106. Epub 2008/09/17. doi:10.1016/j.yexcr.2008.08.013 PMID: 18793634; PubMed Central PMCID: PMC2605728.
53. Hayashi T, Sakamoto S. Radioimmunoassay of human epidermal growth factor - hEGF levels in human body fluids. J Pharmacobiodyn. 1988; 11(3):146-51. PMID: 3261789.
54. Sigismund S, Woelk T, Puri C., Maspero E, Tacchetti C, Transidico P., et al. Clathrin-independentendocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA. 2005; 102(8):2760-5. Epub 2005/02/11. doi:10.1073/pnas.0409817102 PMID: 15701692; PubMed Central PMCID: PMC549482.
55. Muthuswamy SK. Trastuzumab resistance: all roads lead to SRC. Nat Med. 2011; 17(4):416-8. Epub 2011/04/09. doi:10.1038/nm0411-416 PMID: 21475230.